EpiCentre

Epicentre is a biotechnology company specializing in the development and manufacture of enzymes and kits for genomics, proteomics, and molecular biology research. Founded in 1987 and based in Madison, Wisconsin, the company became widely recognized for its innovative Nextera technology, which utilizes in vitro transposition to simplify DNA library preparation for next-generation sequencing. In 2011, Epicentre was acquired by Illumina for approximately 80 million dollars, significantly enhancing Illumina's sequencing workflow capabilities. The company's product portfolio includes a variety of high-performance enzymes, such as T7 R&DNA Polymerase and various transposases, which are essential for advanced molecular research and diagnostic development. Today, much of Epicentre's core technology is integrated into Illumina's market-leading genomic solutions.